Blair William & Co. IL Lowers Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Key Points

• Blair William & Co. IL has reduced its stake in Alnylam Pharmaceuticals by 7.4%, now owning 11,078 shares valued at approximately $2.99 million.
• Despite some institutional sell-offs, other investors like Whipplewood Advisors and Bessemer Group significantly increased their holdings in Alnylam Pharmaceuticals by over 176% and 208% respectively during the same period.
• Several analysts have raised price targets for Alnylam Pharmaceuticals, with JPMorgan increasing its target from $348 to $475 and UBS raising theirs from $403 to $550.

Blair William & Co. IL trimmed its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 7.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,078 shares of the biopharmaceutical company's stock after selling 884 shares during the quarter. Blair William & Co. IL's holdings in Alnylam Pharmaceuticals were worth $2,991,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in ALNY. Whipplewood Advisors LLC raised its position in shares of Alnylam Pharmaceuticals by 208.8% in the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 71 shares during the period. Bessemer Group Inc. raised its holdings in Alnylam Pharmaceuticals by 176.9% in the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 69 shares during the period. Park Square Financial Group LLC purchased a new position in Alnylam Pharmaceuticals during the fourth quarter worth approximately $28,000. Colonial Trust Co SC purchased a new position in Alnylam Pharmaceuticals during the fourth quarter worth approximately $35,000. Finally, Washington Trust Advisors Inc. increased its position in shares of Alnylam Pharmaceuticals by 53.5% in the first quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company's stock valued at $47,000 after buying an additional 61 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 19,297 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $306.00, for a total value of $5,904,882.00. Following the completion of the transaction, the chief executive officer owned 48,948 shares of the company's stock, valued at $14,978,088. This trade represents a 28.28% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 1.50% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

ALNY has been the topic of a number of research analyst reports. JPMorgan Chase & Co. lifted their price target on shares of Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the company an "overweight" rating in a research note on Wednesday. Wells Fargo & Company lifted their target price on shares of Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the company an "equal weight" rating in a research report on Friday, August 1st. UBS Group upped their price target on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Scotiabank lifted their price objective on Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the stock a "sector outperform" rating in a report on Friday, August 1st. Finally, BMO Capital Markets increased their target price on Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the company an "outperform" rating in a report on Tuesday, June 24th. Four research analysts have rated the stock with a hold rating and twenty-four have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $403.92.

Alnylam Pharmaceuticals Stock Up 1.6%

Alnylam Pharmaceuticals stock opened at $435.10 on Friday. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.98 and a current ratio of 2.80. The firm has a 50 day moving average price of $329.10 and a 200 day moving average price of $283.50. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $436.77. The company has a market capitalization of $57.03 billion, a PE ratio of -176.15 and a beta of 0.25.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. The company had revenue of $773,689 billion during the quarter, compared to analysts' expectations of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%. Alnylam Pharmaceuticals's revenue for the quarter was up 17.3% on a year-over-year basis. During the same period last year, the business posted ($0.13) EPS. Research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.